¹é½Å ¼öŹÁ¦Á¶ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 70¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á
2023³â 42¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº 2023-2030³â µ¿¾È ¿¬Æò±Õ 7.5%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 70¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼¿¡¼ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¾àµ¶È ¹é½ÅÀº CAGR 7.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ µ¿¾È 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÒȰ¼ºÈ ¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.0%·Î ÃßÁ¤µË´Ï´Ù.
¹Ì±¹ ½ÃÀå 11¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.5%·Î ¼ºÀå Àü¸Á
¹Ì±¹ÀÇ ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº 2023³â 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 11.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 3.3%¿Í 6.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 4.2%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®
¹é½Å ¼öŹÁ¦Á¶°¡¶õ ¹«¾ùÀ̸ç, Çö´ë ÇコÄɾ¼ ¿Ö Áß¿äÇѰ¡?
¹é½Å ¼öŹÁ¦Á¶´Â ¹é½Å Á¦Á¶¸¦ Àü¹® °³¹ß ¹× Á¦Á¶ À§Å¹±â°ü(CDMO)¿¡ À§Å¹ÇÏ´Â ¹æ½ÄÀÔ´Ï´Ù. CDMO´Â °øÁ¤ °³¹ß, ½ºÄÉÀϾ÷, ´ë·® »ý»ê, Á¦ÇüÈ, ÃæÁø, Æ÷Àå, ǰÁú °ü¸® µî ¿£µå Åõ ¿£µå ¼ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ¹é½Å Á¦Á¶¾÷ü´Â CDMO¿Í ÆÄÆ®³Ê½ÊÀ» ¸Î°í CDMOÀÇ Àü¹® Áö½Ä, ±â¼ú ¹× Àåºñ¸¦ Ȱ¿ëÇÏ¿© º¸´Ù ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº »ý»ê´É·ÂÀ» È®ÀåÇϰíÀÚ ÇÏ´Â ´ëÇü Á¦¾à»ç³ª ÀÚü ÀÎÇÁ¶ó¸¦ ±¸ÃàÇÏÁö ¾Ê°íµµ ¹é½Å °³¹ßÀ» °¡¼ÓÈÇØ¾ß ÇÏ´Â ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.
¹é½Å ¼öŹÁ¦Á¶ÀÇ Á߿伺Àº »ý»ê·®À» ºü¸£°Ô È®ÀåÇϰí À¯¿¬¼ºÀ» ³ôÀ̸ç, ƯÈ÷ Àü¿°º´À̳ª Áúº´ ¹ß»ý°ú °°ÀÌ ¼ö¿ä°¡ ¸¹Àº ½Ã±â¿¡ Àü ¼¼°è°¡ ¹é½Å¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÏ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. CDMO´Â ´ë±Ô¸ð »ý»êÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á ¹é½ÅÀÌ º¸´Ù ½Å¼ÓÇϰí Àú·ÅÇÑ ºñ¿ëÀ¸·Î ½ÃÀå¿¡ Ãâ½ÃµÉ ¼ö ÀÖµµ·Ï µ½°í, Àü ¼¼°è °øÁߺ¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇÕ´Ï´Ù. Àü·Ê ¾ø´Â ¼¼°è ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â µ¥ ÀÖ¾î À§Å¹»ý»êÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °Á¶Çß½À´Ï´Ù. ¹é½Å ÆÄÀÌÇÁ¶óÀÎÀÌ °¨¿°¼º Áúȯ, ¾Ï, ½ÅÁ¾ º´¿øÃ¼ µî ¹é½Å ÆÄÀÌÇÁ¶óÀÎÀÌ Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ´Ù¾çȵʿ¡ µû¶ó, À§Å¹»ý»êÀº È¿À²ÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç È®Àå °¡´ÉÇÑ ¹é½Å Á¦Á¶¸¦ Áö¿øÇÏ´Â µ¥ ÀÖ¾î ÇʼöÀûÀÔ´Ï´Ù.
±â¼úÀÇ ¹ßÀüÀº ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?
±â¼úÀÇ ¹ßÀüÀ¸·Î ¹é½Å À§Å¹ »ý»êÀÇ È¿À²¼º, È®À强 ¹× ǰÁúÀÌ Å©°Ô Çâ»óµÇ¾î ¹é½Å °³¹ß ¹× »ý»êÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ±âÁ¸ÀÇ ½ºÅ×Àθ®½º ½ºÆ¿ ¹ÙÀÌ¿À¸®¾×ÅÍ¿¡ ºñÇØ À¯¿¬¼º, ó¸® ½Ã°£ ´ÜÃà, ¿À¿° À§Çè °¨¼Ò µîÀÇ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÏȸ¿ë ½Ã½ºÅÛÀº ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å, mRNA ¹é½Å, ÀçÁ¶ÇÕ ´Ü¹éÁú ¹é½Å »ý»ê¿¡ ƯÈ÷ À¯¸®Çϸç, CDMO´Â ´Ù¸¥ À¯ÇüÀÇ ¹é½ÅÀ» ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀ¸·Î ÀüȯÇÒ ¼ö ÀÖ½À´Ï´Ù.
mRNA ¹é½Å Á¦Á¶ÀÇ ¹ßÀüÀº À§Å¹ »ý»êÀÇ Çüŵµ º¯È½Ã۰í ÀÖÀ¸¸ç, CDMO´Â Ư¼ö mRNA ÇÕ¼º, ĸ½¶È ¹× ÁöÁú ³ª³ëÀÔÀÚ(LNP) ±â¼ú¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ºü¸¥ ½ºÄÉÀϾ÷°ú ³ôÀº ¼öÀ²À» °¡´ÉÇÏ°Ô ÇÏ¿© COVID-19»Ó¸¸ ¾Æ´Ï¶ó µ¶°¨, RSV, ¾Ï°ú °°Àº ´Ù¸¥ Áúº´¿¡ ´ëÇÑ mRNA ¹é½ÅÀÇ °³¹ßÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È¿Í µðÁöÅÐÈ´Â ¹é½Å Á¦Á¶ ¶óÀÎÀ» Çõ½ÅÇÏ¿© °øÁ¤ °ü¸®¸¦ °³¼±Çϰí, ÀÎÀû ¿À·ù¸¦ ÁÙÀ̰í, ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô Çϸç, AI¿Í ¸Ó½Å·¯´× ÅøÀ» ¹é½Å Á¦Á¶ ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ¿© Á¦Á¶ °øÁ¤À» ÃÖÀûÈÇϰí, ¹èÄ¡ Àϰü¼ºÀ» °ÈÇϸç, ǰÁú °ü¸®¸¦ °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
ÀÚµ¿ ¹«±Õ ÃæÀü ½Ã½ºÅÛ, µ¿°á°ÇÁ¶ ¹× ÷´Ü Æ÷Àå ¼Ö·ç¼ÇÀº ¹é½ÅÀÇ ¾ÈÁ¤¼º, À¯Åë±âÇÑ ¹× À¯ÅëÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¹é½ÅÀÌ ¾ÈÀüÇϰí È¿À²ÀûÀ¸·Î Á¦Á¶ ¹× Æ÷ÀåµÇ¾î ¾ö°ÝÇÑ ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇϵµ·Ï º¸ÀåÇϸç, CDMO´Â ¶ÇÇÑ Áß´Ü ¾ø´Â »ý»ê°ú ½Ç½Ã°£ ǰÁú º¸ÁõÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¿¬¼Ó »ý»ê °øÁ¤À» µµÀÔÇÏ¿© È¿À²¼ºÀ» ³ôÀÌ°í ºñ¿ëÀ» Àý°¨Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¹é½Å »ý»ê´É·Â°ú ¼Óµµ¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ´õ ºü¸£°í ÀûÀÀ·ÂÀÌ ¶Ù¾î³ª¸ç È®Àå °¡´ÉÇÑ Á¦Á¶ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù.
´Ù¾çÇÑ ¹é½Å À¯Çü¿¡ ´ëÇÑ ¹é½Å ¼öŹÁ¦Á¶ÀÇ »õ·Î¿î Àû¿ë »ç·Ê´Â?
¹é½Å ¼öŹÁ¦Á¶´Â Ư¼öÇÑ Á¦Á¶ ´É·Â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ´Ù¾çÇÑ ¹é½Å À¯Çü¿¡ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. »ý¹é½Å, ºÒȰ¼ºÈ ¹é½Å, ¼ºêÀ¯´Ö ¹é½Å°ú °°Àº ÀüÅëÀûÀÎ ¹é½ÅÀÇ °æ¿ì, CDMO´Â Á¦Á¶ °ü¸® ¹× ǰÁú °ü¸® ±âÁØ(GMP)¿¡ ºÎÇÕÇÏ´Â ´ë±Ô¸ð Á¦Á¶ ½Ã¼³À» Á¦°øÇÏ¿© °íǰÁúÀÇ ½Å·ÚÇÒ ¼ö ÀÖ´Â »ý»ê¹°À» º¸ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ¼Ò¾Æ¸¶ºñ, °£¿°, È«¿ª°ú °°Àº Áúº´À» ´ë»óÀ¸·Î ÇÏ´Â Á¤±â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡ ¿©ÀüÈ÷ ÇʼöÀûÀÔ´Ï´Ù. ƯÈ÷ °øÁß º¸°ÇÀ» À§ÇØ ¹é½Å¿¡ ´ëÇÑ Á¢±ÙÀÌ ÇʼöÀûÀÎ ÁßÀú¼Òµæ ±¹°¡¿¡¼ °è¾à Á¦Á¶¾÷ü´Â Àü ¼¼°è ¿¹¹æÁ¢Á¾ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ »ý»ê ±Ô¸ð¸¦ È®´ëÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
mRNA ¹é½Å, DNA ¹é½Å, ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å°ú °°Àº Â÷¼¼´ë ¹é½Å »ý»êÀº À§Å¹ »ý»êÀÇ Áß¿äÇÑ ÃÊÁ¡ÀÌ µÇ°í ÀÖÀ¸¸ç, CDMO´Â mRNA ÇÕ¼º, º¤ÅÍ Á¦Á¶, ¹ÙÀÌ·¯½º ĸ½¶È µîÀÇ ±â´ÉÀ» Á¦°øÇÏ¿© ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Ç÷§ÆûÀ» Áö¿øÇϱâ À§ÇØ ºü¸£°Ô ÀûÀÀÇϰí ÀÖ½À´Ï´Ù. ºü¸£°Ô ÀûÀÀÇØ ¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, COVID-19 ÆÒµ¥¹Í »óȲ¿¡¼ ½Å¼ÓÇÑ °³¹ß°ú È®À强À» º¸¿©ÁØ mRNA ¹é½ÅÀº CDMO°¡ µ¶ÀÚÀûÀ¸·Î ´ëÀÀÇÒ ¼ö Àִ Ư¼öÇÑ Á¦Á¶ °øÁ¤À» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, ¼Ò·®À¸·Î ȯÀÚº° ¸ÂÃãÇü ¾Ï ¹é½ÅÀÌ ÁÖ¸ñ¹Þ°í ÀÖ´Â °Íµµ ¼Ò±Ô¸ð Á¤¹Ð »ý»ê¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â À¯¿¬ÇÑ »ý»ê üÁ¦¸¦ °®Ãá CDMO¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
°¨¿°º´ ¹é½Å ¿Ü¿¡µµ À§Å¹»ý»êÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ¾Ë·¹¸£±â¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á¿ë ¹é½ÅÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ¼¼Æ÷ ±â¹Ý Ç÷§Æû, ÀçÁ¶ÇÕ ´Ü¹éÁú, »õ·Î¿î º¸Á¶Á¦ µî º¹ÀâÇÑ Á¦Á¶ ¹æ¹ýÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹À¸¸ç, CDMO´Â »ý¸í°øÇÐ ±â¾÷µé°ú Çù·ÂÇÏ¿© ÀÌ·¯ÇÑ Ä¡·á¿ë ¹é½ÅÀ» °³¹ß ¹× »ý»êÇÏ¿© È¿À²ÀûÀÎ Á¦Á¶ ¹× ±ÔÁ¦ ±âÁØ Áؼö¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½Å À¯Çü¿¡¼ À§Å¹»ý»êÀÌ È®´ëµÇ°í ÀÖ´Â °ÍÀº ´Ù¾çÇÑ Á¦Á¶ ¼ö¿ä¸¦ ÃæÁ·Çϰí, °³¹ß ±â°£À» ´ÜÃàÇϸç, »ý¸íÀ» ±¸ÇÒ ¼ö ÀÖ´Â ¹é½Å¿¡ ´ëÇÑ Æø³ÐÀº Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â CDMOÀÇ Áß¿äÇÑ ¿ªÇÒÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.
¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?
¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀº ¹é½Å ¼ö¿ä Áõ°¡, ¹é½Å ÆÄÀÌÇÁ¶óÀÎ È®Àå, È®Àå °¡´ÉÇÑ »ý»ê ¼Ö·ç¼ÇÀÇ Çʿ伺 µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â ½ÅÈï Àü¿°º´, °èÀýÀû À¯Çà(¿¹: µ¶°¨), Áý´Ü ¿¹¹æ Á¢Á¾ Ä·ÆäÀÎÀÇ Çʿ伺¿¡ ÈûÀÔ¾î ¹é½Å¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä Áõ°¡À̸ç, COVID-19 ÆÒµ¥¹ÍÀº È®Àå °¡´ÉÇÏ°í ½Å¼ÓÇÑ ¹é½Å »ý»êÀÇ ½Ã±Þ¼ºÀ» ºÎ°¢½ÃÄÑ ¼¼°è ¹é½Å Á¢Á¾ ¸ñÇ¥¸¦ ´Þ¼ºÇϱâ À§ÇØ À§Å¹ »ý»êÀÌ Áß¿äÇÏ´Ù´Â °ÍÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ¸ñÇ¥¸¦ ´Þ¼ºÇÏ´Â µ¥ ÀÖ¾î ¾Æ¿ô¼Ò½ÌÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» ÀÔÁõÇß½À´Ï´Ù. Á¦¾àȸ»ç¿Í Á¤ºÎ°¡ Àü¿°º´¿¡ ´ëºñÇÏ°í ¹é½ÅÀ» ºñÃàÇϱâ À§ÇØ ÅõÀÚÇÏ¸é¼ CDMOÀÇ ¼Áö ´É·Â¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁ® ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
°¨¿°º´ ¹× Ä¡·á¿ë mRNA, DNA, ¹ÙÀÌ·¯½º º¤ÅÍ, ´Ü¹éÁú ±â¹Ý ¹é½Å °³¹ß µî ¹é½Å ÆÄÀÌÇÁ¶óÀÎÀÇ ´Ù¾çȵµ À§Å¹»ý»ê¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷, ½ºÅ¸Æ®¾÷, Çмú ±â°üÀº »ó¾÷Àû ±Ô¸ð·Î ¹é½ÅÀ» »ý»êÇÒ ¼ö ÀÖ´Â ÀÎÇÁ¶ó¸¦ °®ÃßÁö ¸øÇÑ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ CDMO´Â ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ¹é½ÅÀ» ½ÃÀå¿¡ Ãâ½ÃÇÏ´Â µ¥ ÇʼöÀûÀÎ ÆÄÆ®³Ê°¡ µÇ°í ÀÖ½À´Ï´Ù. ¾Ï ¹é½Å µîÀ» Ÿ±êÀ¸·Î ÇÏ´Â mRNA ¹é½ÅÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, mRNA ÇÕ¼º, ÁöÁú ³ª³ëÀÔÀÚ Ä¸½¶È, ÃæÀü ¹× ¸¶¹«¸® ¼ºñ½º µî Àü¹®ÀûÀÎ À§Å¹ »ý»ê´É·Â¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ƯÈ÷ ÁßÀú¼Òµæ ±¹°¡ÀÇ ¹é½Å Á¦Á¶ ¿ª·® È®´ë¸¦ À§ÇÑ ±ÔÁ¦ Áö¿ø°ú Á¤ºÎÀÇ ³ë·Âµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ´Â ÀÎÇÁ¶ó, ÆÄÆ®³Ê½Ê, CDMO¿ÍÀÇ ±â¼úÀÌÀü °è¾à¿¡ ÅõÀÚÇÏ¿© ÇöÁö »ý»ê´É·ÂÀ» È®º¸ÇÏ°í ¹é½Å¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. °ø±Þ Áß´ÜÀ» ¿ÏÈÇÏ°í ¹é½ÅÀÇ ÇüÆò¼ºÀ» °³¼±Çϱâ À§ÇØ º¸´Ù ź·ÂÀûÀÎ ¼¼°è °ø±Þ¸ÁÀ» ±¸ÃàÇÏ·Á´Â ¿òÁ÷ÀÓÀº À§Å¹ Á¦Á¶¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í °¡¼ÓȽÃ۰í ÀÖ½À´Ï´Ù. ¹é½Å ±â¼ú, Á¦Á¶ ¹æ¹ý, µðÁöÅÐÈÀÇ Çõ½ÅÀ¸·Î ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº °øÁߺ¸°Ç, ÆÒµ¥¹Í ´ëºñ, ¹é½Å Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Àü ¼¼°èÀûÀÎ ³ë·Â¿¡ ÈûÀÔ¾î °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÁÖ¸ñ 34°³»ç)
- Ajinomoto Althea, Inc.
- Albany Molecular Research, Inc.
- Catalent, Inc.
- Cobra Bio
- Cytovance Biologics
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Icon plc
- IDT Biologika
- KBI Biopharma
- Lonza
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå °³¿ä
- ÁÖ¿ä ±â¾÷
- ½ÃÀå µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ
- ¼¼°è ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ºÐ¼®
- ¹Ì±¹
- ij³ª´Ù
- ÀϺ»
- Áß±¹
- À¯·´
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ¿µ±¹
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- È£ÁÖ
- Àεµ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¾Æ¸£ÇîÆ¼³ª
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- À̶õ
- À̽º¶ó¿¤
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
Á¦4Àå °æÀï
ksm
Global Vaccine Contract Manufacturing Market to Reach US$7.0 Billion by 2030
The global market for Vaccine Contract Manufacturing estimated at US$4.2 Billion in the year 2023, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Attenuated Vaccine, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Inactivated Vaccine segment is estimated at 7.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 11.5% CAGR
The Vaccine Contract Manufacturing market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
Global Vaccine Contract Manufacturing Market - Key Trends & Drivers Summarized
What Is Vaccine Contract Manufacturing, and Why Is It So Crucial in Modern Healthcare?
Vaccine Contract Manufacturing involves outsourcing vaccine production to specialized contract development and manufacturing organizations (CDMOs). These CDMOs provide end-to-end services, including process development, scale-up, bulk production, formulation, fill-finish, packaging, and quality control. Vaccine manufacturers partner with CDMOs to leverage their expertise, technology, and facilities, allowing for faster, more cost-effective production. This approach is particularly beneficial for large pharmaceutical companies looking to expand capacity and for biotech startups that need to accelerate vaccine development without building their own infrastructure.
The importance of vaccine contract manufacturing lies in its ability to rapidly scale up production, enhance flexibility, and ensure global access to vaccines, particularly in times of high demand, such as during pandemics or disease outbreaks. By enabling large-scale production, CDMOs help ensure that vaccines reach markets more quickly and at a lower cost, supporting public health initiatives worldwide. The COVID-19 pandemic underscored the critical role of contract manufacturing in meeting unprecedented global demand, with CDMOs helping pharmaceutical companies achieve faster approvals and large-scale vaccine distribution. As vaccine pipelines continue to expand and diversify—including vaccines for infectious diseases, cancer, and emerging pathogens—contract manufacturing has become indispensable in supporting efficient, reliable, and scalable vaccine production.
How Are Technological Advancements Shaping the Vaccine Contract Manufacturing Market?
Technological advancements have significantly improved the efficiency, scalability, and quality of Vaccine Contract Manufacturing, driving innovation in vaccine development and production. One of the major developments is the adoption of single-use bioreactor technology, which offers flexibility, faster turnaround times, and reduced contamination risks compared to traditional stainless-steel bioreactors. Single-use systems are particularly advantageous for producing viral vector vaccines, mRNA vaccines, and recombinant protein vaccines, allowing CDMOs to switch between different vaccine types quickly and cost-effectively.
Advancements in mRNA vaccine production have also reshaped contract manufacturing, with CDMOs investing heavily in specialized mRNA synthesis, encapsulation, and lipid nanoparticle (LNP) technologies. These innovations allow for rapid scale-up and higher yields, supporting the development of mRNA vaccines not only for COVID-19 but also for other diseases like influenza, RSV, and cancer. Automation and digitalization are transforming vaccine production lines, improving process control, reducing human error, and enabling real-time monitoring. AI and machine learning tools are being integrated into vaccine manufacturing workflows to optimize production processes, enhance batch consistency, and accelerate quality control.
Another key advancement is in fill-finish technology, where automated aseptic filling systems, lyophilization (freeze-drying), and advanced packaging solutions have improved vaccine stability, shelf life, and distribution. These innovations ensure that vaccines are produced and packaged safely and efficiently, meeting stringent regulatory standards. CDMOs are also incorporating continuous manufacturing processes, which enable uninterrupted production and real-time quality assurance, improving efficiency and reducing costs. These technological innovations not only enhance the capacity and speed of vaccine production but also align with global demands for faster, more adaptable, and scalable manufacturing solutions.
What Are the Emerging Applications of Vaccine Contract Manufacturing Across Different Vaccine Types?
Vaccine Contract Manufacturing is finding expanding applications across a diverse range of vaccine types, driven by increasing demand for specialized production capabilities. For traditional vaccines like live-attenuated, inactivated, and subunit vaccines, CDMOs provide large-scale production facilities that meet Good Manufacturing Practice (GMP) standards, ensuring high-quality and reliable output. These vaccines remain critical for routine immunization programs, targeting diseases like polio, hepatitis, and measles. Contract manufacturers play a crucial role in scaling up production to meet global immunization needs, particularly in low- and middle-income countries where vaccine access is vital for public health.
The production of next-generation vaccines, such as mRNA vaccines, DNA vaccines, and viral vector vaccines, has become a significant focus for contract manufacturing. CDMOs have rapidly adapted to support these innovative platforms, providing capabilities for mRNA synthesis, vector production, and viral encapsulation. For example, mRNA vaccines, which demonstrated rapid development and scalability during the COVID-19 pandemic, require specialized manufacturing processes that CDMOs are uniquely equipped to handle. The increasing focus on personalized cancer vaccines, which involve small-batch, patient-specific production, is also driving demand for CDMOs with flexible manufacturing setups that can accommodate small-scale, precision-focused production.
In addition to infectious disease vaccines, contract manufacturing is expanding into therapeutic vaccines targeting cancer, autoimmune diseases, and allergies. These vaccines often require complex production methods, including cell-based platforms, recombinant proteins, and novel adjuvant formulations. CDMOs are collaborating with biotech companies to develop and manufacture these therapeutic vaccines, ensuring efficient production and adherence to regulatory standards. The expanding applications of contract manufacturing across these vaccine types reflect its critical role in meeting diverse production needs, accelerating development timelines, and enabling broader access to life-saving vaccines.
What Drives Growth in the Vaccine Contract Manufacturing Market?
The growth in the Vaccine Contract Manufacturing market is driven by several factors, including the increasing demand for vaccines, the expansion of vaccine pipelines, and the need for scalable production solutions. One of the primary growth drivers is the rising global demand for vaccines, fueled by emerging infectious diseases, seasonal epidemics (e.g., influenza), and the need for mass immunization campaigns. The COVID-19 pandemic highlighted the urgency of scalable, rapid vaccine production, demonstrating the vital role of contract manufacturing in achieving global vaccination goals. As pharmaceutical companies and governments invest in pandemic preparedness and vaccine stockpiling, the reliance on CDMOs for surge capacity has increased, driving market growth.
The diversification of vaccine pipelines, with the development of mRNA, DNA, viral vector, and protein-based vaccines for both infectious diseases and therapeutic applications, has also fueled the demand for contract manufacturing. Biotech companies, startups, and academic institutions often lack the infrastructure to produce vaccines at commercial scale, making CDMOs essential partners in bringing these innovative vaccines to market. The rapid growth of mRNA vaccines beyond COVID-19—targeting conditions like influenza, RSV, Zika virus, and personalized cancer vaccines—has further driven the need for specialized contract manufacturing capabilities, including mRNA synthesis, lipid nanoparticle encapsulation, and fill-finish services.
Regulatory support and government initiatives aimed at expanding vaccine manufacturing capacity, particularly in low- and middle-income countries, have also contributed to market growth. Governments are investing in infrastructure, partnerships, and technology transfer agreements with CDMOs to ensure local production capacity and improve access to vaccines. The push for more resilient global supply chains, driven by the need to mitigate supply disruptions and improve vaccine equity, has further accelerated demand for contract manufacturing. With ongoing innovations in vaccine technologies, production methods, and digitalization, the Vaccine Contract Manufacturing market is poised for robust growth, supported by global efforts to improve public health, pandemic preparedness, and vaccine accessibility.
Select Competitors (Total 34 Featured) -
- Ajinomoto Althea, Inc.
- Albany Molecular Research, Inc.
- Catalent, Inc.
- Cobra Bio
- Cytovance Biologics
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Icon plc
- IDT Biologika
- KBI Biopharma
- Lonza
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Vaccine Contract Manufacturing - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Demand for Vaccines Drives Adoption of Contract Manufacturing Services
- Expanding Role of CMOs (Contract Manufacturing Organizations) Propels Vaccine Manufacturing
- Focus on Cost-Effective Vaccine Manufacturing Boosts CMO Market
- Growing Role of Outsourcing in Vaccine Production Sets the Stage for CMO Growth
- Regulatory Push for Faster Vaccine Approvals Drives CMO Market Expansion
- Increasing Investments in Biologics Propel Vaccine Contract Manufacturing
- Demand for mRNA Vaccine Production Enhances Contract Manufacturing Opportunities
- Case Overview: Demand for Fill-and-Finish Services Boosts Vaccine CMO Adoption
- Growing Use of Single-Use Bioprocessing in Vaccine Manufacturing Bodes Well for CMOs
- Demand for High-Quality Vaccine Production Sets the Stage for CMO Market
- Push for Pandemic Preparedness Drives Vaccine Contract Manufacturing
- Expansion of Vaccines for Emerging Diseases Boosts CMO Demand
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 11: World Historic Review for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 12: World 16-Year Perspective for Subunit-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 14: World Historic Review for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 15: World 16-Year Perspective for Toxoid-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 17: World Historic Review for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 18: World 16-Year Perspective for DNA-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 20: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 21: World 16-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 23: World Historic Review for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 24: World 16-Year Perspective for Veterinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 25: World Vaccine Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: USA 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 29: USA Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: USA 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 35: Canada Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- JAPAN
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 41: Japan Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- CHINA
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: China Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: China 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 47: China Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: China Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: China 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- EUROPE
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- FRANCE
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 59: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: France Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 61: France 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 63: France Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 64: France 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- GERMANY
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 65: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 67: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- ITALY
- TABLE 71: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 73: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 77: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 79: UK 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 82: UK 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- SPAIN
- TABLE 83: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 84: Spain Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 85: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 86: Spain Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 88: Spain 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- RUSSIA
- TABLE 89: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 90: Russia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 91: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 92: Russia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 94: Russia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 96: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 97: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 100: Rest of Europe 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 109: Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- AUSTRALIA
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 110: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 111: Australia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 112: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 113: Australia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 115: Australia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- INDIA
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 116: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 117: India Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 118: India 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 119: India Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 120: India Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 121: India 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- SOUTH KOREA
- TABLE 122: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 123: South Korea Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 124: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 127: South Korea 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- REST OF ASIA-PACIFIC
- TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 129: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- LATIN AMERICA
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Vaccine Contract Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 139: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 142: Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- ARGENTINA
- TABLE 143: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 144: Argentina Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 145: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 148: Argentina 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- BRAZIL
- TABLE 149: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 150: Brazil Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 151: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 154: Brazil 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- MEXICO
- TABLE 155: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 156: Mexico Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 157: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 160: Mexico 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- REST OF LATIN AMERICA
- TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 162: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 163: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 166: Rest of Latin America 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- MIDDLE EAST
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Vaccine Contract Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 169: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 172: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 175: Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- IRAN
- TABLE 176: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 177: Iran Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 178: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 179: Iran Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 181: Iran 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- ISRAEL
- TABLE 182: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 183: Israel Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 184: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 185: Israel Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 187: Israel 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- SAUDI ARABIA
- TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 189: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 190: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 193: Saudi Arabia 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- UNITED ARAB EMIRATES
- TABLE 194: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 195: UAE Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 196: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 197: UAE Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 199: UAE 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- REST OF MIDDLE EAST
- TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 201: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 202: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 205: Rest of Middle East 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
- AFRICA
- Vaccine Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 206: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 207: Africa Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 208: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2014, 2024 & 2030
- TABLE 209: Africa Recent Past, Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 211: Africa 16-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2014, 2024 & 2030
IV. COMPETITION